Abstract
Phosphodiesterase 2 (PDE2) is a ubiquitous enzyme whose major role is to hydrolyze the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the central nervous system, pharmacological inhibition of PDE2 results in boosted cAMP and/or cGMP signaling, which is responsible for series of changes in protein expression relevant to psychiatric and learning and memory disorders, such as depression, anxiety, and cognition deficits in Alzheimer’s disease. In the periphery, inhibition of PDE2 exhibits beneficial effects in the diseased cardiovascular system, the respiratory system, skeletal muscles and Candida albicans-caused systemic infections. Even though blood-brain barrier penetration properties and selectivity of currently available PDE2 inhibitors have hindered them from entering clinical trials, PDE2 is still of great potential therapeutic values in different categories of diseases, and there is demand for development of new generation drugs targeting PDE2 for treatment of diseases in central nervous and peripheral systems.
Keywords: Phosphodiesterase 2 (PDE2), cyclic AMP (cAMP), cyclic GMP (cGMP), emotion, cognition, cardiovascular health, respiratory health, systemic infection.
Current Pharmaceutical Design
Title:The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Volume: 21 Issue: 3
Author(s): Chong Zhang, Yingcong Yu, Lina Ruan, Chuang Wang, Jianchun Pan, Jonathan Klabnik, Lindsay Lueptow, Han-Ting Zhang, James M. O’Donnell and Ying Xu
Affiliation:
Keywords: Phosphodiesterase 2 (PDE2), cyclic AMP (cAMP), cyclic GMP (cGMP), emotion, cognition, cardiovascular health, respiratory health, systemic infection.
Abstract: Phosphodiesterase 2 (PDE2) is a ubiquitous enzyme whose major role is to hydrolyze the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the central nervous system, pharmacological inhibition of PDE2 results in boosted cAMP and/or cGMP signaling, which is responsible for series of changes in protein expression relevant to psychiatric and learning and memory disorders, such as depression, anxiety, and cognition deficits in Alzheimer’s disease. In the periphery, inhibition of PDE2 exhibits beneficial effects in the diseased cardiovascular system, the respiratory system, skeletal muscles and Candida albicans-caused systemic infections. Even though blood-brain barrier penetration properties and selectivity of currently available PDE2 inhibitors have hindered them from entering clinical trials, PDE2 is still of great potential therapeutic values in different categories of diseases, and there is demand for development of new generation drugs targeting PDE2 for treatment of diseases in central nervous and peripheral systems.
Export Options
About this article
Cite this article as:
Zhang Chong, Yu Yingcong, Ruan Lina, Wang Chuang, Pan Jianchun, Klabnik Jonathan, Lueptow Lindsay, Zhang Han-Ting, O’Donnell James M. and Xu Ying, The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems, Current Pharmaceutical Design 2015; 21 (3) . https://dx.doi.org/10.2174/1381612820666140826115245
DOI https://dx.doi.org/10.2174/1381612820666140826115245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Status Epilepticus in the Immature Rodent Brain Alters the Dynamics of Autophagy
Current Neurovascular Research Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Role of Molecular Hydrogen in Skin Diseases and its Impact in Beauty
Current Pharmaceutical Design Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry Melatonin Attenuates Methamphetamine-Induced Neurotoxicity
Current Pharmaceutical Design Nanoparticles: A Promising Therapeutic Approach in Atherosclerosis
Current Drug Delivery Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Pharmacological Characteristics of Parenteral IGF-I Administration
Current Pharmaceutical Biotechnology F508del-CFTR Rescue: A Matter of Cell Stress Response
Current Pharmaceutical Design Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Sphingolipids as Emerging Drug Targets: Therapeutic Applications of Ceramide Analogs
Drug Design Reviews - Online (Discontinued) ERRATUM
Current Neuropharmacology Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design P2X7 Receptor Orchestrates Multiple Signalling Pathways Triggering Inflammation, Autophagy and Metabolic/Trophic Responses
Current Medicinal Chemistry